823 related articles for article (PubMed ID: 25830421)
21. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
Choi SH; Cesar A; Snow TAC; Saleem N; Arulkumaran N; Singer M
Int J Antimicrob Agents; 2023 Sep; 62(3):106905. PubMed ID: 37385561
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
23. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
[TBL] [Abstract][Full Text] [Related]
24. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
[TBL] [Abstract][Full Text] [Related]
25. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
26. In non-ICU suspected CAP, β-lactam was noninferior to β-lactam-macrolide or fluoroquinolone for 90-d mortality.
Fekete T
Ann Intern Med; 2015 Sep; 163(6):JC5. PubMed ID: 26370032
[No Abstract] [Full Text] [Related]
27. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
[TBL] [Abstract][Full Text] [Related]
28. Predictors for individual patient antibiotic treatment effect in hospitalized community-acquired pneumonia patients.
Simonetti AF; van Werkhoven CH; Schweitzer VA; Viasus D; Carratalà J; Postma DF; Oosterheert JJ; Bonten MJM
Clin Microbiol Infect; 2017 Oct; 23(10):774.e1-774.e7. PubMed ID: 28336384
[TBL] [Abstract][Full Text] [Related]
29. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.
Ambroggio L; Test M; Metlay JP; Graf TR; Blosky MA; Macaluso M; Shah SS
Pediatr Pulmonol; 2016 May; 51(5):541-8. PubMed ID: 26367389
[TBL] [Abstract][Full Text] [Related]
30. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
[TBL] [Abstract][Full Text] [Related]
31. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
Bratzler DW; Ma A; Nsa W
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
[TBL] [Abstract][Full Text] [Related]
32. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.
Lee JS; Giesler DL; Gellad WF; Fine MJ
JAMA; 2016 Feb; 315(6):593-602. PubMed ID: 26864413
[TBL] [Abstract][Full Text] [Related]
33. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
[TBL] [Abstract][Full Text] [Related]
34. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
35. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy.
Okumura J; Shindo Y; Takahashi K; Sano M; Sugino Y; Yagi T; Taniguchi H; Saka H; Matsui S; Hasegawa Y;
Respirology; 2018 May; 23(5):526-534. PubMed ID: 29239493
[TBL] [Abstract][Full Text] [Related]
36. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
[TBL] [Abstract][Full Text] [Related]
38. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
39. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
40. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
